These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 31023626)
1. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626 [TBL] [Abstract][Full Text] [Related]
2. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. Pandyra AA; Mullen PJ; Goard CA; Ericson E; Sharma P; Kalkat M; Yu R; Pong JT; Brown KR; Hart T; Gebbia M; Lang KS; Giaever G; Nislow C; Moffat J; Penn LZ Oncotarget; 2015 Sep; 6(29):26909-21. PubMed ID: 26353928 [TBL] [Abstract][Full Text] [Related]
3. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987 [TBL] [Abstract][Full Text] [Related]
4. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. Pandyra A; Mullen PJ; Kalkat M; Yu R; Pong JT; Li Z; Trudel S; Lang KS; Minden MD; Schimmer AD; Penn LZ Cancer Res; 2014 Sep; 74(17):4772-82. PubMed ID: 24994712 [TBL] [Abstract][Full Text] [Related]
5. Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non-Small Cell Lung Carcinogenesis. Zhang T; Bai R; Wang Q; Wang K; Li X; Liu K; Ryu J; Wang T; Chang X; Ma W; Bode AM; Xia Q; Song Y; Dong Z Cancer Prev Res (Phila); 2019 Dec; 12(12):837-848. PubMed ID: 31554629 [TBL] [Abstract][Full Text] [Related]
6. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. Longo J; Smirnov P; Li Z; Branchard E; van Leeuwen JE; Licht JD; Haibe-Kains B; Andrews DW; Keats JJ; Pugh TJ; Trudel S; Penn LZ Leukemia; 2021 Mar; 35(3):796-808. PubMed ID: 32665698 [TBL] [Abstract][Full Text] [Related]
7. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522 [TBL] [Abstract][Full Text] [Related]
8. Endogenous sterol intermediates of the mevalonate pathway regulate HMGCR degradation and SREBP-2 processing. Chen L; Ma MY; Sun M; Jiang LY; Zhao XT; Fang XX; Man Lam S; Shui GH; Luo J; Shi XJ; Song BL J Lipid Res; 2019 Oct; 60(10):1765-1775. PubMed ID: 31455613 [TBL] [Abstract][Full Text] [Related]
9. The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase. Maciejak A; Leszczynska A; Warchol I; Gora M; Kaminska J; Plochocka D; Wysocka-Kapcinska M; Tulacz D; Siedlecka J; Swiezewska E; Sojka M; Danikiewicz W; Odolczyk N; Szkopinska A; Sygitowicz G; Burzynska B BMC Biotechnol; 2013 Aug; 13():68. PubMed ID: 24128347 [TBL] [Abstract][Full Text] [Related]
10. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Longo J; Pandyra AA; Stachura P; Minden MD; Schimmer AD; Penn LZ Mol Oncol; 2020 Oct; 14(10):2533-2545. PubMed ID: 32749766 [TBL] [Abstract][Full Text] [Related]
11. A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Longo J; Hamilton RJ; Masoomian M; Khurram N; Branchard E; Mullen PJ; Elbaz M; Hersey K; Chadwick D; Ghai S; Andrews DW; Chen EX; van der Kwast TH; Fleshner NE; Penn LZ Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):630-637. PubMed ID: 32203069 [TBL] [Abstract][Full Text] [Related]
12. Statins and prostate cancer-hype or hope? The biological perspective. Longo J; Freedland SJ; Penn LZ; Hamilton RJ Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):650-656. PubMed ID: 35768578 [TBL] [Abstract][Full Text] [Related]
13. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Goard CA; Chan-Seng-Yue M; Mullen PJ; Quiroga AD; Wasylishen AR; Clendening JW; Sendorek DH; Haider S; Lehner R; Boutros PC; Penn LZ Breast Cancer Res Treat; 2014 Jan; 143(2):301-12. PubMed ID: 24337703 [TBL] [Abstract][Full Text] [Related]
14. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Yeganeh B; Wiechec E; Ande SR; Sharma P; Moghadam AR; Post M; Freed DH; Hashemi M; Shojaei S; Zeki AA; Ghavami S Pharmacol Ther; 2014 Jul; 143(1):87-110. PubMed ID: 24582968 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. Li X; Chen YT; Josson S; Mukhopadhyay NK; Kim J; Freeman MR; Huang WC PLoS One; 2013; 8(8):e70987. PubMed ID: 23951060 [TBL] [Abstract][Full Text] [Related]